In Chinese patients with type 2 diabetes, HbA1c decreased significantly from baseline with generic and branded exenatide.
In plain wordsIn Chinese patients with diabetes, both generic and branded exenatide reduced HbA1c from baseline.
- Peptide
- Exenatide (exendin-4)
- Outcome
- DecreaseHbA1c change from baseline
- Study
n = 240
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- Dose not stated · 16 weeksAs given in this study (human).
Measurements
- HbA1c change from baseline
- −1.1%
- generic exenatide group, 16 weeks, SD 1.31
- HbA1c change from baseline
- −1.08%
- branded exenatide group, 16 weeks, SD 1.11
- HbA1c change from baseline
- −12 mmol/mol
- generic exenatide group, 16 weeks, SD 14.3
- HbA1c change from baseline
- −11.8 mmol/mol
- branded exenatide group, 16 weeks, SD 12.1
Source sentences
After 16 weeks of treatment, HbA1c levels decreased significantly from baseline in the two groups, with a reduction of - 1.10% ± 1.31% (- 12.0 mmol/mol ± 14.3 mmol/mol) in the generic exenatide group and - 1.08% ± 1.11% (- 11.8 mmol/mol ± 12.1 mmol/mol) in the branded exenatide group (both P < 0.001).
1 context sentence(design, population, supporting numbers)
A total of 240 patients with T2DM and glycated hemoglobin (HbA1c) ≥ 7% (53 mmol/mol) to ≤ 9.0% (75 mmol/mol) on monotherapy or combination therapy of metformin and insulin secretagogues for at least 3 months were randomized into generic exenatide or branded exenatide groups with a 1:1 ratio for 16 weeks of treatment.